Abcam PLC is a global provider of protein research tools and services, catering to academic institutions, biotechnology companies and pharmaceutical organizations. The company offers an extensive portfolio of high-quality primary and secondary antibodies, recombinant proteins, peptides, assay kits and related reagents designed to accelerate scientific discovery. Abcam’s products support a wide range of applications including Western blot, immunohistochemistry, flow cytometry and enzyme-linked immunosorbent assays (ELISA).
Established in 1998 by a team of scientists and entrepreneurs in Cambridge, England, Abcam has grown through innovation and strategic acquisitions. The company’s research and development efforts focus on developing novel antibody formats, enhancing assay sensitivity and expanding its recombinant protein library. Abcam also provides custom antibody development, protein expression services and on-demand assay development, enabling researchers to tackle complex biological questions.
In 2014, Abcam became a publicly traded company on the London Stock Exchange, reinforcing its commitment to growth and global expansion. Over the years, the company has extended its footprint through acquisitions of complementary life science businesses, broadening its product range and geographic reach. In November 2023, Abcam completed a strategic acquisition by Danaher Corporation, positioning it to leverage Danaher’s global infrastructure while continuing to operate under the Abcam brand.
Headquartered in Cambridge, United Kingdom, Abcam maintains a presence in over 30 countries with major research hubs in the United States, Europe and Asia. Under the leadership of CEO David Armstrong and Chairman Jonathan Milner, the company remains focused on delivering reliable, high-performance tools that enable scientists worldwide to advance research in oncology, immunology, neuroscience and beyond.
AI Generated. May Contain Errors.
